Antiemetics

CLS Holdings USA, Inc. Announces Acquisition Target "In Good Health" Receives Massachusetts State Approval for Final Recreational License

Retrieved on: 
Tuesday, September 17, 2019

As a result of this approval, In Good Health becomes one of the first 30 dispensaries in the state of Massachusetts to offer both THC and CBD based cannabis products for recreational use.

Key Points: 
  • As a result of this approval, In Good Health becomes one of the first 30 dispensaries in the state of Massachusetts to offer both THC and CBD based cannabis products for recreational use.
  • David Noble, President ofIn Good Health, commented, We are extremely pleased with this final license approval to open up shortly for adult use sales from the Cannabis Control Commission of the great state of Massachusetts.
  • CLS anticipates that it will complete the acquisition of In Good Health in January 2020, subject to satisfaction of applicable closing conditions.
  • See CLS Holdings USA filings with the SEC and on its SEDAR profile at www.sedar.com for additional details.

Sensorion Announces Two Presentations at AAO-HNSF 2019 in New Orleans

Retrieved on: 
Tuesday, September 17, 2019

The first poster is entitled SENS-111 Maintains Cognitive Functions in Healthy Volunteers in Contrast to Meclizine.

Key Points: 
  • The first poster is entitled SENS-111 Maintains Cognitive Functions in Healthy Volunteers in Contrast to Meclizine.
  • The data is further confirmed by patients self-assessed measures on the Stanford Sleepiness Scale (SSS).
  • In contrast, Meclizine 50mg has been demonstrated to negatively impact vigilance and showed sedative effects.
  • The impact of these findings on the long-term recovery from acute vertigo will need to be confirmed in clinical trials.

Syqe Enters Into Distribution Agreement With TerrAscend to Bring Revolutionary Medical Cannabis Treatment to Canada

Retrieved on: 
Monday, September 16, 2019

We are thrilled to be working with TerrAscend to share our groundbreaking technology with a progressive market at the forefront of medical cannabis treatment."

Key Points: 
  • We are thrilled to be working with TerrAscend to share our groundbreaking technology with a progressive market at the forefront of medical cannabis treatment."
  • TerrAscend, through its wholly owned subsidiaries TerrAscend Canada and Solace Health Network, will lead marketing, distribution and sales efforts across Canada.
  • Through Solace Health's patient-centric online platform and medical coverage assistance, as well as its wide network of medical professionals, TerrAscend is uniquely positioned for success with the Syqe treatment in the Canadian medical cannabis market.
  • As part of the agreement, TerrAscend will utilize their platform to both provide high quality guidance to patients on use of the Syqe device and educate the medical community on the benefits of medical cannabis and the Syqe treatment.

Franchise Cannabis’s German Subsidiary ACA Müller Commits to Purchase of Medical Cannabis from MJardin’s Halifax Facility Due to Rapid Growth in German Patient Demand

Retrieved on: 
Monday, September 16, 2019

ACA Mller has committed to purchase 250 kgs a month of high THC (>20%) medical cannabis flower during Q1 to Q3 2020 at a set price throughout the year.

Key Points: 
  • ACA Mller has committed to purchase 250 kgs a month of high THC (>20%) medical cannabis flower during Q1 to Q3 2020 at a set price throughout the year.
  • We look forward to working with Franchise as our European distribution partner in this high growth region.
  • This supply relationship will allow us to increase our sales volumes to meet growing demand, said Clifford Starke, Franchise Cannabiss CEO.
  • The German market added 20,000 new patients last quarter, and our inventories are being sold out month after month.

Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies

Retrieved on: 
Thursday, September 12, 2019

(OTC: MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its major investment company AXIM Biotechnologies, Inc .

Key Points: 
  • (OTC: MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its major investment company AXIM Biotechnologies, Inc .
  • ("AXIM Biotech" or "AXIM") (OTCQB: AXIM) has begun manufacturing its cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC).
  • "We look forward to the findings of AXIM's upcoming dronabinol chewing gum studies and understanding how it may help those undergoing chemotherapy."
  • AXIM Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products.

SIML Proscere Bioscience in Negotiations With Major Pharmaceutical Company for a $200M Deal

Retrieved on: 
Wednesday, September 11, 2019

Grass Valley, CA, Sept. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) ("Simlatus" or the "Company") announces today negotiations with a major pharmaceutical company in Europe regarding a potential $200M initial order.

Key Points: 
  • Grass Valley, CA, Sept. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) ("Simlatus" or the "Company") announces today negotiations with a major pharmaceutical company in Europe regarding a potential $200M initial order.
  • The company initially discussed its Hybrid Cold/Water Alcohol based CBD Extraction system in Europe last December-2018 with a major pharmaceutical company.
  • Negotiations are gaining ground while Proscere Bioscience is positioning itself to supply the pharmaceutical industry with CBD extraction systems to produce pharmaceutical-grade THC and CBD as a replacement for opiate based Schedule-II prescription drugs.
  • Proscere Bioscience will be on this radar for manufacturing the extraction processes to produce these special cannabis compounds.

Dr. Reddy's Laboratories Announces the Launch of Fosaprepitant for Injection in the U.S. Market

Retrieved on: 
Wednesday, September 11, 2019

We are pleased to be among the first generics to launch this product, explains Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddys Laboratories.

Key Points: 
  • We are pleased to be among the first generics to launch this product, explains Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddys Laboratories.
  • This is a great addition to our injectable portfolio in the U.S. market as we continue to augment our product offering and drive growth for the hospital segment.
  • The EMEND for Injection brand had an U.S. sales of approximately $279 million MAT for the most recent twelve months ending in July 2019 according to IQVIA Health*.
  • Dr. Reddys Fosaprepitant for Injection is available in 150 mg single-dose vial for reconstitution.

Nextleaf Solutions Granted U.S. Patent for THC and CBD Oil Processing

Retrieved on: 
Tuesday, September 10, 2019

This most recently issued patent integrates a process by which brine is introduced to the crude oil to efficiently remove water-soluble compounds, impurities, and any other trace elements of treatment media.

Key Points: 
  • This most recently issued patent integrates a process by which brine is introduced to the crude oil to efficiently remove water-soluble compounds, impurities, and any other trace elements of treatment media.
  • The result is a highly pure input, leading to faster processing times for further patented post-extraction processing, resulting in a lower cost per milligram for the highly refined THC or CBD concentrate.
  • Nextleaf ownsa portfolio of five (5) issued and 25 pending patents pertaining to theproduction of high-purity, cannabinoid rich distillate, a key ingredient used in the manufacturing of standardized THC and CBD infused products.
  • Nextleaf Solutions trades as OILS on the Canadian Securities Exchange (CSE: OILS), OILFF on the OTCQB Market inthe United States(OTCQB:OILFF) andL0MAon the Frankfurt Stock Exchange (FSE:L0MA)

Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies

Retrieved on: 
Tuesday, September 10, 2019

In the coming months, AXIM intends to conduct a bioequivalence study between its chewing gum with dronabinol and an FDA-approved synthetic capsule.

Key Points: 
  • In the coming months, AXIM intends to conduct a bioequivalence study between its chewing gum with dronabinol and an FDA-approved synthetic capsule.
  • The Company plans to provide evidence that the Companys chewing gum with dronabinol can serve as an alternative to orally ingested dronabinol for the treatment of symptoms associated with chemotherapy.
  • AXIM plans to formulate its gum with various amounts of dronabinol, including 2.5 mg, 5 mg and 10 mg of dronabinol, for the study.
  • AXIM Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products.

RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit

Retrieved on: 
Monday, September 9, 2019

Our research and operational efforts are supported by our partnership with Noramco, Inc. for clinical and commercial supply of dronabinol.

Key Points: 
  • Our research and operational efforts are supported by our partnership with Noramco, Inc. for clinical and commercial supply of dronabinol.
  • We anticipate continuing this effort with potential collaborations and/or partnerships for formulation development, clinical development and ultimately commercialization.
  • RespireRx plans to develop a proprietary dronabinol formulation to optimize the dose and duration of action for treating OSA.
  • The Company does not intend to update or revise any forward-looking statements to reflect new information, future events or otherwise.